Literature DB >> 31080101

Testosterone Deficiency: A Review and Comparison of Current Guidelines.

Jethro C C Kwong1, Yonah Krakowsky2, Ethan Grober3.   

Abstract

BACKGROUND: There is much controversy regarding the appropriate evaluation and management of testosterone deficiency (TD). AIM: To compare current guidelines on the evaluation and management of TD to provide clarity for patients and clinicians, as well as to highlight areas of controversy.
METHODS: A literature search of MEDLINE, Embase, Cochrane Library, and various association websites was performed to identify guidelines for TD. OUTCOMES: Key aspects in the approach were compared, with a focus on the biochemical definition (cutoff) for low testosterone (T), principles of management, and recommendations for testosterone therapy (TTh) in special patient populations.
RESULTS: Guidelines from the Canadian Medical Association Journal, American Urological Association, European Association of Urology, Endocrine Society, International Society for Sexual Medicine, and British Society for Sexual Medicine were included for review. Recommendations were generally consistent across guidelines. Key differences include the biochemical cutoff for low T, and recommendations for patients with low to normal T, prostate cancer, or cardiovascular disease. We highlight several case scenarios in which management differs depending on the guideline adopted. CLINICAL IMPLICATIONS: Although general diagnostic and management principles are in agreement across the guidelines, notable differences may impact patient diagnosis and eligibility for TTh. STRENGTHS & LIMITATIONS: Only guidelines written in English were included. The quality of the included guidelines was not evaluated, but this was beyond the scope of this review.
CONCLUSION: We highlight the limitations of relying exclusively on guidelines in managing patients with TD. Kwong JCC, Krakowsky Y, Grober E. Testosterone Deficiency: A Review and Comparison of Current Guidelines. J Sex Med 2019;16:812-820.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Cardiovascular Disease; Low to Normal Testosterone; Male Hypogonadism; Prostate Cancer; Testosterone Deficiency; Testosterone Therapy

Mesh:

Substances:

Year:  2019        PMID: 31080101     DOI: 10.1016/j.jsxm.2019.03.262

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  9 in total

1.  Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene.

Authors:  Lina E Aguirre; Georgia Colleluori; David Robbins; Richard Dorin; Vallabh O Shah; Rui Chen; Irum Zeb Jan; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal
Journal:  Endocrine       Date:  2019-07-19       Impact factor: 3.633

Review 2.  The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.

Authors:  L Di Luigi; F Pigozzi; P Sgrò; L Frati; A Di Gianfrancesco; M Cappa
Journal:  J Endocrinol Invest       Date:  2019-11-16       Impact factor: 4.256

3.  Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis.

Authors:  Jemma Hudson; Moira Cruickshank; Richard Quinton; Lorna Aucott; Magaly Aceves-Martins; Katie Gillies; Shalender Bhasin; Peter J Snyder; Susan S Ellenberg; Mathis Grossmann; Thomas G Travison; Emily J Gianatti; Yvonne T van der Schouw; Marielle H Emmelot-Vonk; Erik J Giltay; Geoff Hackett; Sudarshan Ramachandran; Johan Svartberg; Kerry L Hildreth; Kristina Groti Antonic; Gerald B Brock; J Lisa Tenover; Hui Meng Tan; Christopher Ho Chee Kong; Wei Shen Tan; Leonard S Marks; Richard J Ross; Robert S Schwartz; Paul Manson; Stephen Roberts; Marianne Skovsager Andersen; Line Velling Magnussen; Rodolfo Hernández; Nick Oliver; Frederick Wu; Waljit S Dhillo; Siladitya Bhattacharya; Miriam Brazzelli; Channa N Jayasena
Journal:  Lancet Healthy Longev       Date:  2022-06

Review 4.  Epidemiology of Male Hypogonadism.

Authors:  Arthi Thirumalai; Bradley D Anawalt
Journal:  Endocrinol Metab Clin North Am       Date:  2022-02-08       Impact factor: 4.748

5.  The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer.

Authors:  Jose M Flores; Helen L Bernie; Eduardo Miranda; Bruno Nascimento; Elizabeth Schofield; Nicole Benfante; Sigrid Carlsson; John P Mulhall
Journal:  J Sex Med       Date:  2022-02-05       Impact factor: 3.937

6.  The importance of SHBG and calculated free testosterone for the diagnosis of symptomatic hypogonadism in HIV-infected men: a single-centre real-life experience.

Authors:  Letizia Chiara Pezzaioli; Eugenia Quiros-Roldan; Simone Paghera; Teresa Porcelli; Filippo Maffezzoni; Andrea Delbarba; Melania Degli Antoni; Carlo Cappelli; Francesco Castelli; Alberto Ferlin
Journal:  Infection       Date:  2020-12-08       Impact factor: 3.553

7.  Editorial Comment: Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer.

Authors:  Valter Javaroni
Journal:  Int Braz J Urol       Date:  2022 Jan-Feb       Impact factor: 1.541

Review 8.  Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations.

Authors:  Ahmed Al-Sharefi; Richard Quinton
Journal:  Endocrinol Metab (Seoul)       Date:  2020-09-22

Review 9.  Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure.

Authors:  Baris Gencer; Marco Bonomi; Maria Pia Adorni; Cesare R Sirtori; François Mach; Massimiliano Ruscica
Journal:  Rev Endocr Metab Disord       Date:  2021-02-22       Impact factor: 6.514

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.